<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82573">
  <stage>Registered</stage>
  <submitdate>30/01/2008</submitdate>
  <approvaldate>13/02/2008</approvaldate>
  <actrnumber>ACTRN12608000080325</actrnumber>
  <trial_identification>
    <studytitle>Bariatric Surgery in Morbidly Obese Type 2 Diabetic Patients</studytitle>
    <scientifictitle>A randomised trial of adjunction intensive psychological, dietary and cultural management versus standard guidelines-based care to maximise weight loss among high-risk subjects with type 2 diabetes mellitus and morbid obesity treated with bariatric surgery</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 Diabetes</healthcondition>
    <healthcondition>Morbid Obesity</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Intensive wrap around regimen comprising intensive psychological assessment/counselling, cultural support, intensive dietetic assessment/counselling and an exercise programme. The duration of this intervention is 6 months pre-operatively and 12 months post-operatively. The exact nature of the regimen will be tailored to the participant on a case by case basis.</interventions>
    <comparator>Standard guideline-based care comprising of post surgical clinic follow-up.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in body mass index (BMI).</outcome>
      <timepoint>12 months after surgery.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in HbA1c as measured by a blood test.</outcome>
      <timepoint>1 year after surgery.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Type 2 diabetes
Morbid Obesity - BMI &gt;35</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Diabetic nephropathy.
A significant malabsorptive or gastrointestinal disorder.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/01/2008</anticipatedstartdate>
    <actualstartdate>22/05/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate>20/05/2009</actualenddate>
    <samplesize>60</samplesize>
    <actualsamplesize>68</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate>7/12/2011</anticipatedlastvisitdate>
    <actuallastvisitdate>7/12/2011</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Middlemore Clinical Trials</primarysponsorname>
    <primarysponsoraddress>Private Bag 93311
Otahuhu
Auckland</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Counties Manukau District Health Board (CMDHB)</fundingname>
      <fundingaddress>Private Bag 93311 
Otahuhu
Auckland</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Middlemore Clinical Trials</fundingname>
      <fundingaddress>Private Bag 93311
Otahuhu
Auckland</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study comprises a randomised trial of intensive wrap around management versus standard guideline-based care. Sixty (60) patients with type 2 diabetes and morbid obesity (BMI = 35) will be enrolled. Patients will attend on average nine (9) scheduled study visits over the course of the study. Those found to be eligible after the baseline assessments will be randomised to receive a wrap around regimen comprising intensive psychological assessment/counselling, cultural support, intensive dietetic assessment/counselling and an exercise programme or standard guideline-based care in a 1:1 ratio. All participants (i.e. intensive management and standard care) will undergo a bariatric surgery procedure 6-months after randomisation. The total duration of follow-up is 18 months.</summary>
    <trialwebsite />
    <publication>NA</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Northern X Regional Ethics Committee</ethicname>
      <ethicaddress>Ministry of Health
Private Bag 92522
Auckland</ethicaddress>
      <ethicapprovaldate>11/01/2008</ethicapprovaldate>
      <hrec>NTX/07/06/053</hrec>
      <ethicsubmitdate>10/10/2007</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Brandon Orr-Walker</name>
      <address>Middlemore Hospital
Private Bag 93311
Otahuhu
Auckland</address>
      <phone>+64 9 276 0044 extn 8068</phone>
      <fax />
      <email>BOWalker@middlemore.co.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mrs</title>
      <name>Marie White</name>
      <address>CCRep 
Private Bag 93311
Otahuhu
Auckland</address>
      <phone>+64 9 276 0044 extn 2275</phone>
      <fax />
      <email>MWhite@middlemore.co.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Catherine Howie</name>
      <address>Middlemore Clinical Trials
PO Box 93311
Auckland 1640</address>
      <phone>+ 64 9 2760044 Ext 2917</phone>
      <fax>+64 9 250 3828</fax>
      <email>catherine.howie@mmclintrials.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Brandon Orr Walker</name>
      <address>Middlemore Hospital 
100 Hospital Rd 
Auckland 2025</address>
      <phone>+64 9 2760000</phone>
      <fax />
      <email>brandon.or-walker@middlemore.co.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>